Development of nociceptin receptor (NOP) agonists and antagonists

Medicinal Research Reviews

Volumn 31, Issue 4, 2011, Pages 605-648

  Mustazza, Carlo ^a   Bastanzio, Giuditta ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Nociceptin; NOP receptor ligands; Opioids; Structure activity relationship

Indexed keywords

7 [4 (2,6 DICHLOROPHENYL) 1 PIPERIDINYLMETHYL] 6,7,8,9 TETRAHYDRO 1 METHYL 5H BENZOCYCLOHEPTEN 5 OL; 8 (2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL) 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; [8 (1 NAPHTHYLMETHYL) 4 OXO 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DEC 3 YL]ACETIC ACID METHYL ESTER; BENZIMIDAZOLE DERIVATIVE; BUPRENORPHINE; CYCLOHEXYLAMINE DERIVATIVE; ETORPHINE; GLYCINE; GUANOSINE; INDOLE DERIVATIVE; LIGAND; N (4 AMINO 2 METHYL 6 QUINOLINYL) 2 (4 ETHYLPHENOXYMETHYL)BENZAMIDE; NALFURAFINE; NALOXONE BENZOYLHYDRAZONE; NHC 63 0532; NOCICEPTIN RECEPTOR AGONIST; NOCICEPTIN RECEPTOR ANTAGONIST; NORTROPANE DERIVATIVE; OPIATE AGONIST; PEPTIDE; PIMOZIDE; PIPERIDINE DERIVATIVE; POTASSIUM CHANNEL HERG; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; RO 65 6570; SCH 221510; SPIROXATRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; W 212393; ZP 120;

ANOREXIA; ANXIETY; ANXIETY DISORDER; ARTICLE; COCAINE DEPENDENCE; CONGESTIVE HEART FAILURE; COUGHING; DEPRESSION; DRUG DEPENDENCE; DRUG DEVELOPMENT; DRUG SUBSTITUTION; HUMAN; HYPERTENSION; NEUROPATHIC PAIN; NONHUMAN; OBESITY; PAIN; PARKINSON DISEASE; PHYSIOLOGY; PRURITUS; RESPIRATION DEPRESSION; URINE INCONTINENCE;

AMINO ACID SEQUENCE; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; OPIOID PEPTIDES; PEPTIDES; RECEPTORS, OPIOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955786304     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20197     Document Type: Article

References (203)

1. Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, Caput D, Vassart G, Meunier JC. ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization. FEBS Lett 1994;341:33-38.
2. Cox BM, Chavkin C, Christie MJ, Civelli O, Evans C, Hamon MD, Hoellt V, Kieffer B, Kitchen I, McKnight AT, Meunier JC, Portoghese PS. Opioid receptors. In: Girdlestone D, editor. The IUPHAR compendium of receptor characterization and classification. London: IUPHAR Media Ltd; 2000. pp 321-333.
3. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B, Mazarguil H, Vassart G, Parmentier M, Costentin J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995;377:532-535.
4. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FR, Jr, Civelli O. Orphanin FQ: A neuropeptide that activates an opioid-like G-protein coupled receptor. Science 1995;270:792-794.
5. 1 receptor: Molecular pharmacology and signalling mechanisms. Neurosignals 2002;11:197-212.
6. Hawes BE, Graziano MP, Lambert DG. Cellular action of nociceptin: Transduction mechanisms. Peptides 2000;21:961-967.
7. Marti M, Stocchi S, Paganini F, Mela F, De Risi C, Calò G, Guerrini R, Barnes TA, Lambert DG, Beani L, Bianchi C, Morari M. Pharmacological prophiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. Br J Pharmacol 2003;138:91-98.
8. Xu L, Okuda-Ashitaka E, Matsumura S, Mabuchi T, Okamoto S, Sakimura K, Mishina M, Ito S. Signal pathways coupled to activation of neuronal nitric oxide synthase in the spinal cord by nociceptin/orphanin FQ. Neuropharmacology 2007;52:1318-1325.
9. Mollereau C, Mouledous L. Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 2000;21:907-917.
10. Andoh T, Yageta Y, Takeshima H, Kuraishi Y. Intradermal nociceptin elicits itch-associated responses through leukotriene B(4) in mice. J Invest Dermatol 2004;123:196-201.
11. Granata F, Potenza RL, Fiori A, Strom R, Caronti B, Molinari P, Donsante S, Citro G, Iacovelli L, De Blasi A, Ngomba RT, Palladini G, Passarelli F. Expression of OP4 (ORL1, NOP1) receptors in vascular endothelium. Eur J Pharmacol 2003;482:17-23.
12. Mogil JS, Pasternak GW. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 2001;53:381-415.
13. Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP. Nociceptin/orphanin FQ peptide receptors: Pharmacology and clinical implications. Curr Drug Targets 2007;8:117-135.
14. Lambert DG. The nociceptin/orphanin FQ receptor: A target with a broad therapeutical potential. Nat Rev Drug Discov 2008;7:694-710.
15. Bignan GC, Connoly PJ, Middleton SA. Recent advances towards the discovery of ORL-1 receptor agonists and antagonists. Expert Opin Ther Pat 2005;15:357-388.
16. Lazzeri M, Calò G, Spinelli M, Malaguti S, Guerrini R, Salvadori S, Beneforti P, Regoli D, Turini D. Daily intravesical instillation of 1mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: A multicenter, placebo controlled, randomized exploratory study. J Urol 2006;176:2098-2102.
17. Lufty K, Cowan A. Buprenorphine: A unique drug with complex pharmacology. Curr Neuropharmacol 2004;2:395-402.
18. Montoya ID, Gorelick DA, Preston KI, Schroeder JR, Umbricht A, Cheskin LJ, Lange WR, Contoreggi C, Johnson RE, Fudala PJ. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 2004;75:34-48.
19. Spagnolo B, Calò G, Polgar WE, Jiang F, Olsen CM, Berzetei-Gurske I, Khroyan TV, Husbands SM, Lewis JW, Toll L, Zaveri NT. Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol 2008;153:609-619.
20. Calò G, Bigoni R, Rizzi A, Guerrini R, Salvadori S, Regoli D. Nociceptin/orphanin FQ ligands. Peptides 2000;21:935-947.
21. Barlocco D, Toma L, Cignarella G. Non peptidic ligands at the opioid receptor like-1 (ORL-1). Mini Rev Med Chem 2001;1:363-375.
22. Ronzoni S, Peretto I, Giardina GAM. Lead generation and lead optimisation approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists. Expert Opin Ther Pat 2001;11:525-546.
23. Zaveri N. Peptide and non peptide ligands for the nociceptin/orphanin FQ receptor ORL1: Research tools and potential therapeutic agents. Life Sci 2003;73:663-678.
24. Dooley CT, Houghten RA. Orphanin FQ: Receptor binding and analog structure activity relationships in rat brain. Life Sci 1996;59:PL23-PL29.
25. Reinscheid RK, Ardati A, Monsma FJ, Jr, Civelli O. Structure-activity relationship studies on the novel neuropeptide orphanin FQ. J Biol Chem 1996;271:14163-14168.
26. Butour JL, Moisand C, Mazarguil H, Mollereau C, Meunier JC. Recognition and activation of the opioid receptor-like ORL1 receptor by nociceptin, nociceptin analogs and opioids. Eur J Pharmacol 1997;321:97-103.
27. Salvadori S, Guerrini R, Calò G, Regoli D. Structure-activity studies on nociceptin/orphanin FQ: From full agonist, to partial agonist, to pure antagonist. Farmaco 1999;54:810-825.
28. Shimohigashi Y, Hatano R, Fujita T, Nakashima R, Nose T, Sujaku T, Saigo A, Shinjo K, Nagahisa A. Sensitivity of opioid receptor-like receptor ORL-1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide. J Biol Chem 1996;271:23642-23645.
29. Varani K, Rizzi A, Calò G, Bigoni R, Toth G, Guerrini R, Gessi S, Salvadori S, Borea PA, Regoli D. Pharmacology of [Tyr1]nociceptin analogs: Receptor binding and bioassay studies. Naunyn Schmiedebergs Arch Pharmacol 1999;360:270-277.
30. Guerrini R, Calò G, Rizzi A, Bianchi C, Lazarus LH, Salvadori S, Temussi PA, Regoli D. Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem 1997;40:1789-1793.
31. 2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med Chem 1998;41:3360-3366.
32. 2 in rat. Eur J Pharmacol 1999;376:R1-R3.
33. Guerrini R, Calò G, Bigoni R, Rizzi A, Varani K, Toth G, Gessi S, Hashiba E, Hashimoto Y, Lambert DG, Borea PA, Tomatis R, Salvadori S, Regoli D. Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor. J Med Chem 2000;43:2805-2813.
34. 2, a pure and selective nociceptin/orphanin FQ receptor antagonist. J Pept Res 2001;57:215-222.
35. 2: Identification of highly potent agonists of the nociceptin/orphanin FQ receptor. J Med Chem 2001;44:3956-3964.
36. 2 peptide bond. Bioorg Med Chem Lett 2003;13:365-368.
37. Bobrova I, Vlaskovska M, Kasakov L, Surovoy A, Egorova N, Johansson LE, Karsnas P, Terenius L. A structure-activity study of nociceptin-(1-13)-peptide amide. Synthesis of analogues substituted in positions 0, 1, 3, 4 and 10. Eur J Med Chem 2003;38:687-694.
38. 3. Peptides 2004;25:1349-1354.
39. Okada K, Sujaku T, Chuman Y, Nakashima R, Nose T, Costa T, Yamada Y, Yokoyama M, Nagahisa A, Shimohigashi Y. Highly potent nociceptin analog containing the Arg-Lys triple repeat. Biochem Biophys Res Commun 2000;278:493-498.
40. Okada K, Isozaki K, Li J, Matsushima A, Nose T, Costa T, Shimohigashi Y. Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem 2008;16:9261-9267.
41. 15]nociceptin on ORL1 receptor binding and activation. Bioorg Med Chem Lett 2009;17:5683-5687.
42. 2 analogues modified in 9 and/or 13 position. Bioorg Med Chem Lett 2006;16:4071-4074.
43. Ligeti M, Gündüz Ö, Magyar A, Kató E, Rónai AZ, Vita C, Varga I, Hudecz F, Tóth G, Borsodi A, Benyhe S. Synthesis and biological studies of nociceptin derivatives containing the DTPA chelating group for further labeling with therapeutic radionuclides. Peptides 2005;26:1159-1166.
44. Guerrini R, Calò G, Lambert DG, Carrà G, Arduin M, Barnes TA, McDonald J, Rizzi D, Trapella C, Marzola E, Rowbotham DJ, Regoli D, Salvadori S. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands. J Med Chem 2005;48:1421-1427.
45. Calò G, Guerrini R, Rizzi A, Salvadori S, Burmeister M, Kapusta DR, Lambert DG, Regoli D. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. CNS Drug Rev 2005;11:97-112.
46. Ibba M, Kitayama M, McDonald J, Calò G, Guerrini R, Farkas J, Toth G, Lambert DG. Binding of the novel radioligand [(3)H]UFP-101 to the recombinant human and native rat nociceptin/orphanin FQ receptors. Naunyn Schmiedebergs Arch Pharmacol 2008;378:553-561.
47. Kyle DJ. Conformationally constrained peptides that bind the ORL-1 receptor. Patent EP 1927858 A1, Euro-Celtique S.A., 2005.
48. Zhang C, Miller W, Valenzano KJ, Kyle DJ. Novel, potent ORL-1 receptor agonist peptides containing α-helix-promoting conformational constraints. J Med Chem 2002;45:5280-5286.
49. Arduin M, Spagnolo B, Calò G, Guerrini R, Carrà G, Fischetti C, Trapella C, Marzola E, McDonald J, Lambert DG, Regoli D, Salvadori S. Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with α-α-dialkylated amino acids. Bioorg Med Chem 2007;15:4434-4443.
50. Chang M, Peng YL, Dong SL, Han RW, Li W, Yang DJ, Chen Q, Wang R. Structure-activity studies on different modifications of nociceptin/orphanin FQ: Identification of highly potent agonists and antagonists of its receptor. Regul Pept 2005;130:116-122.
51. 2 of nociceptin/orphanin FQ receptor. Regul Pept 2006;134:75-81.
52. Tancredi T, Carrà G, Guerrini R, Arduin M, Calò G, Regoli D, Salvadori S, Temussi PA. The interaction of highly helical structural mutants with the NOP receptor discloses the role of the address domain of nociceptin/orphanin FQ. Chem Eur J 2005;11:2061-2070.
53. Amodeo P, Guerrini R, Picone D, Salvadori S, Spadaccini R, Tancredi T, Temussi PA. Solution structure of nociceptin peptides. J Peptide Sci 2002;8:497-509.
54. Ambo A, Hamazaki N, Yamada Y, Nakata E, Sasaki Y. Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides. J Med Chem 2001;44:4015-4018.
55. 2. Naunyn Schmiedebergs Arch Pharmacol 2007;375:369-376.
56. Charoenchai L, Wang H, Wang JB, Aldrich JV. High affinity conformationally constrained nociceptin/orphaninFQ(1-13)amide analogues. J Med Chem 2008;51:4385-4387.
57. 2. Naunyn Schmiedebergs Arch Pharmacol 2003;368:528-537.
58. 2, a novel specific radioligand for the nociceptin/orphaninFQ receptor. Naunyn Schmiedebergs Arch Pharmacol 2000;362:538-545.
59. Jinsmaa Y, Takahashi M, Fukunaga H, Yoshikawa M. Retro-nociceptin methylester, a peptide with analgesic and memory-enhancing activity. Life Sci 2000;67:3095-3101.
60. Ligeti M, Bösze S, Csámpai A, Gündüz Ö, Al-Khrasani M, Rónai AZ, Medzihradszky-Schweiger H, Benyhe S, Borsodi A, Hudecz F, Magyar A. Synthesis of enzymatically resistant nociceptin-related peptides containing a carbamic acid residue. J Pept Sci 2006;12:481-490.
61. Dooley CT, Spaeth CG, Berzetei-Gurske IP, Craymer K, Adapa ID, Brandt SR, Houghten RA, Toll L. Binding and in vitro activities of peptides with high affinity for the nociceptin/orphaninFQ receptor, ORL1. J Pharmacol Exp Ther 1997;283:735-741.
62. Berger H, Bigoni R, Albrecht E, Richter RM, Krause E, Bienert M, Calò G. The nociceptin/orphaninFQ receptor ligand acetyl-RYYRIK-amide exhibit antagonistic and agonistic properties. Peptides 2000;21:1131-1139.
63. Larsen BD, Petersen JS, Kapusta DR, Harlow KW. Peptide conjugates modified N- and/or C-terminally by short charged peptide chains. Patent WO 01/98324 A1. Zealand Pharmaceuticals A/S. 2001.
64. Rizzi A, Rizzi D, Marzola G, Regoli D, Larsen BD, Petersen JS, Calò G. Pharmacological characterization of the novel nociceptin/orphaninFQ receptor ligand, ZP120: In vitro and in vivo studies in mice. Br J Pharmacol 2002;137:369-374.
65. Kapusta DR, Thorkildsen G, Kenigs VA, Meier E, Vinge MM, Quist C, Petersen JS. Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphaninFQ receptor partial agonist with sodium-potassium sparing aquaretic activity. J Pharmacol Exp Ther 2005;314:652-660.
66. 2 for receptor binding. J Pept Sci 2002;8:561-569.
67. Kocsis L, Orosz G, Magyar A, Al-Khrasani M, Kató E, Rónai AZ, Bes B, Meunier JC, Gündüz O, Tóth G, Borsodi A, Benyhe S. Nociceptin antagonism: Probing the receptor by N-acetyl oligopeptides. Regul Pept 2004;122:199-207.
68. Gündüz O, Rizzi A, Baldisserotto A, Guerrini R, Spagnolo B, Gavioli EC, Kocsis L, Magyar A, Benyhe S, Borsodi A, Calò G. In vitro and in vivo pharmacological characterization of the nociceptin/orphaninFQ receptor ligand Ac-RYYRIK-ol. Eur J Pharmacol 2006;539:39-48.
69. 3H]Ac-RYYRIK-ol. Neurochem Int 2009;55:458-466.
70. 1 partial agonists and antagonists. J Pept Res 2003;62:191-198.
71. Li J, Isozaki K, Okada K, Matsushima A, Nose T, Costa T, Shimohigashi Y. Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem 2008;16:2635-2644.
72. 2. J Pept Res 2005;66:39-47.
73. Judd AK, Tuttle DJ, Jones RW, Sanchez A, Polgar W, Berzetei-Guske I, Toll L. Structure-activity studies on high-affinity NOP-active hexapeptides. J Pept Res 2004;64:87-94.
74. 2 (Syn 1020) in rodents. Eur J Pharmacol 2007;560:29-35.
75. Judd AK. Nociceptin-based analgesics. Patent US 2008/0221304 A1, Synvax Inc. 2008.
76. 2 and its analogs. J Pept Sci 2007;13:672-678.
77. Ishiyama K, Tereda T, Oyama T, Ohgi T. Peptide derivatives and medicinal compositions. Patent EP 1275657, Nippon Shinyaku Co. Ltd., 2003.
78. Economidou D, Policani F, Angellotti T, Massi M, Terada T, Ciccocioppo R. Effect of novel NOP receptor ligands on food intake in rats. Peptides 2006;27:775-783.
79. Kawano S, Ambo A, Sasaki Y. Synthesis and receptor binding properties of chimeric peptides containing a μ-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide. Bioorg Med Chem Lett 2006;16:4839-4841.
80. Kawano S, Ito R, Nishiyama M, Kubo M, Matsushima T, Minamisawa M, Ambo A, Sasaki Y. Receptor binding properties and antinociceptive effects of chimeric peptides consisting of a μ-opioid receptor agonist and an ORL1 receptor antagonist. Biol Pharm Bull 2007;30:1260-1264.
81. Lapalu S, Moisand C, Marzaguil H, Cambois G, Mollereau C, Meunier JC. Comparison of the structure-activity relationships of nociceptin and dynorphin A using chimeric peptides. FEBS Lett 1997;417:333-336.
82. Reinscheid RK, Higelin J, Henningsen RA, Monsma FJ, Jr, Civelli O. Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities. J Biol Chem 1998;273:1490-1495.
83. Becker JA, Wallace A, Garzon A, Ingallinella P, Bianchi E, Cortese R, Simonin F, Kieffer BL, Pessi A. Ligands for κ-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library. J Biol Chem 1999;274:27513-27522.
84. Halab L, Becker JA, Darula Z, Tourwé D, Kieffer BL, Simonin F, Lubell WD. Probing opioid receptor interactions with azacycloalkane amino acids. Synthesis of a potent and selective ORL1 antagonist. J Med Chem 2002;45:5353-5357.
85. 2. J Med Chem 2004;47:1864-1867.
86. Noda Y, Mamiya T, Nabeshima T, Nishi M, Higashioka M, Takeshima H. Loss of antinociception induced by naloxone benzoylhydrazone in nociceptin receptor-knockout mice. J Biol Chem 1998;273:18047-18051.
87. Ito F. Morphinan hydroxamic acid compounds. Patent US5834478, Pfizer Inc., 1998.
88. Seki T, Awamura S, Kimura C, Ide S, Sakano K, Minami M, Nagase H, Satoh M. Pharmacological properties of TRK-820 on μ-, δ- and κ-opioid receptors and nociceptin receptor. Eur J Pharmacol 1999;376:159-167.
89. Mizoguchi H, Hung KC, Leitermann R, Narita M, Nagase H, Suzuki T, Tseng LF. Blockade of μ-opioid receptor mediated G-protein activation and antinociception by TRK-820 in mice. Eur J Pharmacol 2003;461:35-39.
90. Reidenberg BE, Gale DD, Srinivasan VJ. N-but-3-enyl norbuprenorphine and its use as analgesic. Patent US7125884 B2, Euro-Celtique S.A., 2006.
91. Wnendt S, Strassburger W, Buschmann H, Reiss-Mueller E, Krueger T. Use of morphine derivatives as medicaments for the treatment of neuropathic problems. Patent US6476044 B1, Gruenenthal GmbH, 2002.
92. Chen Z, Miller WS, Shan S, Valenzano KJ. Design and parallel synthesis of piperidine libraries targeting the nociceptin (N/OFQ) receptor. Bioorg Med Chem Lett 2003;13:3247-3252.
93. Ho GD, Bercovici A, Tulshian D, Greenlee WJ, Fawzi A, Smith Torhan A, Zhang H. Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. Bioorg Med Chem Lett 2007;17:3023-3027.
94. Ho GD, Bercovici A, Tulshian D, Greenlee WJ, Fawzi A, Fernandez X, McLeod RL, Smith Torhan A, Zhang H. Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. Bioorg Med Chem Lett 2007;17:3028-3033.
95. Thomsen C, Hohlweg R. Use of 3, 4-substituted piperidines. Patent WO 01/32178 A1, Novo Nordisk A/S, 2001.
96. Zaratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P, Ronzoni S, Giardina GA, Scheideler MA. Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)cis-1-methyl-7-[[4-(2, 6-dichlorophenyl)piperidin-1-yl]methyl]-6, 7, 8, 9-tetrahydro-5H-benzocyclohepthen-5-ol (SB-612111). J Pharmacol Exp Ther 2004;308:454-461.
97. Spagnolo B, Carrà G, Fantin M, Fischetti G, Hebbes C, McDonald J, Barnes TA, Rizzi A, Trapella C, Fanton G, Morari M, Lambert DG, Regoli D, Calò G. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)cis-1-methyl-7-[[4-(2, 6-dichlorophenyl)piperidin-1-yl]methyl]-6, 7, 8, 9-tetrahydro-5H-benzocyclohepthen-5-ol]: In vitro studies. J Pharmacol Exp Ther 2007;321:961-967.
98. Rizzi A, Gavioli EC, Marzola G, Spagnolo B, Zucchini S, Ciccocioppo R, Trapella C, Regoli D, Calò G. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)cis-1-methyl-7-[[4-(2, 6-dichlorophenyl)piperidin-1-yl]methyl]-6, 7, 8, 9-tetrahydro-5H-benzocyclohepthen-5-ol]: In vivo studies. J Pharmacol Exp Ther 2007;321:968-974.
99. + channel. J Med Chem 2008;51:4021-4029.
100. Takahashi H, Sugimoto Y, Yoshizumi T, Kato T, Asai M, Miyazoe H. Cycloalkanopyridine derivatives. Patent EP1726590 A1, Banyu Pharmaceutical Co., 2006.
101. Chen Z. 4-Tetrazolyl-4-phenylpiperidine derivatives for treating pain. Patent EP1803718 B1, Euro-Celtique S.A., 2008.
102. Varty GB, Lu SX, Morgan CA, Cohen-Williams ME, Hodgson RA, Smith-Torhan A, Zhang H, Fawzi AB, Graziano MP, Ho GD, Matasi J, Tulshian D, Coffin VL, Carey GJ. The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis-(2-methylphenyl))methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510). J Pharmacol Exp Ther 2008;326:672-682.
103. Sawutz DG, Brianceau P, Bercovici A, Ho GD, Tulshian D. 8-[bis-(2-chloro-phenyl)-methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxylic acid amide as ligand for the nociceptin receptor ORL-1. Patent WO 2007/050719 A1, Schering Co., 2007.
104. Yang SW, Ho G, Tulshian D, Greenlee WJ, Anthes J, Fernandez X, McLeod RL, Hey JA, Xu X. Discovery of orally active 3-pyridinyl-tropane as a potent nociceptin receptor agonist for the management of cough. J Med Chem 2009;52:5323-5329.
105. Yang SW, Ho G, Tulshian D, Greenlee WJ, Fernandez X, McLeod RL, Eckel S, Anthes J. Structure-activity relationship of 3-substituted N-benzhydryl-nortropane analogs as nociceptin receptor ligands for the treatment of cough. Bioorg Med Chem Lett 2008;18:6340-6343.
106. Yang SW, Ho G, Tulshian D, Greenlee WJ, Tan Z, Zhang H, Smith-Torhan A, Fawzi A, Anthes J, Lu S, Varty G, Fernandez X, McLeod RL, Hey J. Identification of 3-substituted N-benzhydryl-nortropane analogs as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett 2009;19:2482-2486.
107. Ho GD, Anthes J, Bercovici A, Caldwell JP, Cheng KC, Cui X, Fawzi A, Fernandez X, Greenlee WJ, Hey J, Korfmacher W, Lu SX, McLeod RL, Ng F, Smith-Torhan A, Tan Z, Tulshian D, Varty GB, Xu X, Zhang H. The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett 2009;19:2519-2523.
108. Zaveri N, Polgar WE, Olsen CM, Kelson AB, Grundt P, Lewis JW, Toll L. Characterization of opiates, neuroleptics and synthetic analogs at ORL1 and opioid receptor. Eur J Pharmacol 2001;428:29-36.
109. Kawamoto H, Ozaki S, Itoh Y, Miyaji M, Arai S, Nakashima H, Kato T, Ohta H, Iwasawa Y. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R, 4R)]-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). J Med Chem 1999;42:5061-5063.
110. Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Azuma T, Ichikawa D, Nambu H, Iguchi T, Iwasawa Y, Ohta H. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur J Pharmacol 2000;402:45-53.
111. Kawamoto H, Nakashima H, Kato T, Arai S, Kamata K, Iwasawa Y. Synthesis of J-113397, the first potent and selective ORL1 antagonist. Tetrahedron 2001;57:981-986.
112. De Risi C, Pollini GP, Trapella C, Peretto I, Ronzoni S, Giardina GAM. A new synthetic approach to 1-[(3R, 4R)]-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397), the first non-peptide ORL-1 receptor antagonist. Bioorg Med Chem 2001;9:1871-1877.
113. Smith ED, Vinson NA, Zhong D, Berrang BD, Catanzaro JL, Thomas JB, Navarro HA, Gilmour BP, Deschamps J, Carroll FI. A new synthesis of the ORL-1 antagonist 1-[(3R, 4R)]-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay. Bioorg Med Chem 2008;16:822-829.
114. 11C]ethyl-1, 3-dihydro-2H-benzimidazol-2-one as a brain ORL1 receptor imaging agent for positron emission tomography. Nucl Med Biol 2003;30:51-59.
115. Trapella C, Guerrini R, Piccagli L, Calò G, Carrà G, Spagnolo B, Rubini S, Fanton G, Hebbes C, McDonald J, Lambert DG, Regoli D, Salvadori S. Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorg Med Chem 2006;14:692-704.
116. Kyle D, Goehring RR, Shao B. Benzimidazole compounds having nociceptin receptor affinity. Patent US7456198 B2, Purdue Pharma L.P., 2008.
117. Ozaki S, Kawamoto H, Ito Y, Hirano K, Hayashi K, Iwasawa Y. 2-Oxoimidazole derivatives. Patent US6258825, Banyu Pharmaceutical Co., 2001.
118. Hashimoto M, Iwasawa Y, Kawamoto H, Ohta H, Ozaki S, Sagara T, Sakoh H, Satoh A. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivative. Patent EP 1914232, Banyu Pharmaceutical Co. Ltd., 2008.
119. Ito F, Kondo H, Noguchi H, Ohashi Y, Yamagishi T. 4-(2-Keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists. Patent WO/1999/036421, Pfizer Inc., 1999.
120. Palin R, Barn DR, Clark JK, Cottney JE, Cowley PM, Crockatt M, Evans L, Feilden H, Goodwin RR, Griekspoor F, Grove SJA, Houghton AK, Jones PS, Morphy RJ, Smith ARC, Sundaram H, Vrolijk D, Weston MA, Wishart G, Wren P. Synthesis and SAR studies of 3-phenoxypropyl piperidine analogues as ORL1 (NOP) receptor agonists. Bioorg Med Chem Lett 2005;15:589-593.
121. Palin R, Bom A, Clark JK, Evans L, Feilden H, Houghton AK, Jones PS, Montgomery B, Weston MA, Wishart G. Synthesis and evaluation of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic and sedative properties. Bioorg Med Chem 2007;15:1828-1847.
122. Palin R, Clark JK, Evans L, Houghton AK, Jones PS, Prosser A, Wishart G, Yoshiizumi K. Structure-activity relationships and CoMFA of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic properties. Bioorg Med Chem 2008;16:2829-2851.
123. Teshima K, Ciccocioppo R, Massi M. Agent for prophylaxis or treatment of alcohol dependence or drug dependence. Patent WO/2008/050698, Mitsubishi Tanabe Pharma Co., 2008.
124. Teshima K, Minoguchi M, Tounai S, Ashimori A, Eguchi J, Allen CN, Shibata S. Nonphotic entrainment of the circadian body temperature rhythm by the selective ORL1 receptor agonist W-212393 in rats. Br J Pharmacol 2005;146:33-40.
125. Jong L, Zaveri N, Toll L. The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands. Bioorg Med Chem Lett 2004;14:181-185.
126. Chen Z, Goehring RR, Valenzano KJ, Kyle DJ. Design and synthesis of novel small molecule N/OFQ receptor antagonists. Bioorg Med Chem Lett 2004;14:1347-1351.
127. Goehring RR, Chen Z, Kyle D, Victory S. Octahydrobenzimidazolone compounds as analgetics. Patent EP1975164 A2, Euro-Celtique S.A., 2008.
128. Hirao A, Imai A, Sugie Y, Yamada Y, Hayashi S, Toide K. Pharmacological characterization of the newly syntesized nociceptin/orphanin FQ receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxyolitic agent. J Pharmacol Sci 2008;106:361-368.
129. Hayashi S, Hirao A, Imai A, Nakamura H, Murata Y, Ohashi K, Nakata E. Novel non-peptide nociceptin/orphanin FQ receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: Design, synthesis and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug. J Med Chem 2009;52:610-625.
130. Hirao A, Imai A, Sugie Y, Tamura T, Shimokawa H, Toide K. Pharmacological properties of a novel nociceptin/orphanin FQ receptor agonist, 2-(3, 5-dimethylpiperazin-1-yl)-1-[1-(1-methylcyclooctyl)piperidin-4-yl]-1H-benzimidazole, with anxiolytic potential. Eur J Pharmacol 2008;579:189-195.
131. Zaveri NT, Jiang F, Olsen CM, Deschamps JR, Parrish D, Polgar W, Toll L. A novel series of piperidin-4-yl-1, 3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor. J Med Chem 2004;47:2973-2976.
132. Khroyan TV, Zaveri NT, Polgar WE, Orduna J, Olsen C, Jiang F, Toll L. SR 16435 [1-(1-bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/μ-opioid receptor partial agonist: Analgesic and rewarding properties in mice. J Pharmacol Exp Ther 2007;320:934-943.
133. Zaveri N, Yiang F, Olsen C, Polgar W, Toll L. Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP. AAPS J 2005;7:E345-E352.
134. Bignan GC, Battista K, Connolly PJ, Orsini MJ, Liu J, Middleton SA, Reitz AB. 3-(4-piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2, 3-b]pyridines as ligands for the ORL-1 receptor. Bioorg Med Chem Lett 2006;16:3524-3528.
135. Bignan GC, Battista KA, Connolly PJ, Liu JJ, Middleton SA, Orsini MJ, Reitz AB. 3-piperidin-4-yl-indole ORL-1 receptor modulators. Patent US 20080015214, Johnson & Johnson, 2008.
136. Goehring RR, Whitehead JF, Brown K, Islam K, Wen X, Zhou X, Chen Z, Valenzano KJ, Miller WS, Shan S, Kyle DJ. 1, 3-Dihydro-2, 1, 3-benzothiadiazol-2, 2-diones and 3, 4-dihydro-1H-2, 1, 3-benzothiadiazin-2, 2-diones as ligands for the NOP receptor. Bioorg Med Chem Lett 2004;14:5045-5050.
137. Baba Y, Brown KC, Goehring RR, Tsuno N. Heterocyclic-substituted piperidine as ORL-1 ligands. Patent WO/2008/089201, Purdue Pharma L.P.and Shionogi & Co.Ltd, 2008.
138. Sun Q, Goehring RR, Kyle D, Chen Z, Victory S, Whitehead J. 1-(4-Piperidinyl)-1, 3-dihydro-2H-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and ORL1 ligands for the treatment of pain. Patent EP1598340 B1, Euro-Celtique S.A., 2009.
139. Goehring RR, Chen Z, Kyle D, Victory S, Gharagozloo P, Whitehead J. Quinolinone derivatives and their use to treat pain. EP1997818 A2, Euro-Celtique S.A., 2008.
140. Tafesse L. 4-Oxadiazolyl-piperidine compounds and use thereof. Patent US 2008/0319020; Purdue Pharma L.P., 2008.
141. Röver S, Adam G, Cesura AM, Galley G, Jenck F, Monsma FJ, Jr, Wichmann J, Dautzenberg FM. High-affinity, non-peptide agonists for the ORL-1 (orphanin FQ/nociceptin) receptor. J Med Chem 2000;43:1329-1338.
142. Wichmann J, Adam G, Röver S, Cesura AM, Dautzenberg FM, Jenck F. 8-Acenaphthen-1-yl-1-phenyl-1, 3, 8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists. Bioorg Med Chem Lett 1999;9:2343-2348.
143. Röver S, Wichmann J, Jenck F, Adam G, Cesura AM. ORL1 receptor ligands: Structure-activity relationships of 8-cycloalkyl-1-phenyl-1, 3, 8-triaza-spiro[4.5]decan-4-ones. Bioorg Med Chem Lett 2000;10:831-834.
144. Wichmann J, Adam G, Röver S, Hennig M, Scalone M, Cesura AM, Dautzenberg FM, Jenck F. Synthesis of (1S, 3aS)-8-(2, 3, 3a, 4, 5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1, 3, 8-triazaspiro[4.5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. Eur J Med Chem 2000;35:839-851.
145. Schoblock JR. The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity. CNS Drug Rev 2007;13:107-136.
146. Ko MC, Woods JH, Fantegrossi WE, Galuska CM, Wichmann J, Prinssen EP. Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology 2009;34:2088-2096.
147. 11C]methyl-Ro 64-6198 as an ORL1 receptor imaging agent. Nucl Med Biol 2001;28:941-947.
148. Thomsen C, Hohlweg R. (8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1, 3, 8-triaza-spiro[4.5]dec-3-yl)acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist. Br J Pharmacol 2000;131:903-908.
149. Hohlweg R, Watson B, Pettersson I. Novel triazaspirodecanones with high affinity for opioid receptor subtypes. Patent WO/2001/036418, Novo Nordisk A/s, 2001.
150. Ito F, Ohashi Y. 1, 3, 8-Triazaspiro[4, 5]decanone compounds as orl-1 receptor agonists. Patent EP0997464, Pfizer Inc., 2005.
151. Kawamoto H, Ozaki S, Ito Y, Iwazawa Z. 4-oxoimidazolidine-5-spiro-nitrogen containing heterocyclic compound. Patent JP 2000169476, Banyu Pharmaceutical Co., 2000.
152. Battista K, Bignan G, Connolly PJ, Reitz AB, Ross TM, Scott M, Middleton SA, Orsini M. Hydroxy alkyl substituted 1, 3, 8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders. Patent US2009/0124614, Johnson & Johnson, 2009.
153. Mentzel M, Reiche DD, Brückner R, David S, Van Steen BJ, Schön U, Jasserand D, Preuschoff U. Hydronopol derivatives as agonists of human ORL1 receptors. Patent US7241770, Solvay Pharmaceuticals GmbH, 2004.
154. Caldwell JP, Matasi JJ, Zhang H, Fawzi A, Tulshian DB. Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands. Bioorg Med Chem Lett 2007;17:2281-2284.
155. Caldwell JP, Matasi JJ, Fernandez X, McLeod RL, Zhang H, Fawzi A, Tulshian DB. Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands. Part 2. Bioorg Med Chem Lett 2009;19:1164-1167.
156. Chen Z, Victory S. Triazaspiro compounds useful for treating or preventing pain. Patent US7414062, Purdue Pharma L.P., 2008.
157. Bignan GC, Hlasta DJ, Ryan RR. 1, 3, 8-trisubstituted-1, 3, 8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the ORL-1 receptor. Patent US2008/0249122, Johnson & Johnson, 2008.
158. Hansen LBL, Larsen BD, Thorkildsen C, Knudsen CB. Nociceptin analogues and uses thereof. Patent US20080287478 A1, Clark & Elbing LLP, 2008.
159. Guerrini R, Carrà G, Calò G, Trapella C, Marzola E, Rizzi D, Regoli D, Salvadori S. Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: Design, synthesis and in vitro pharmacological activity. J Pept Res 2004;63:477-484.
160. Satoh A, Kato T, Ooi N, Iwasawa Y. 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds. Patent WO/2001/96337, Banyu Pharmaceutical Co., 2001.
161. Hashimoto M, Okamoto O, Ozaki S, Ohta H. 4-oxoimidazolidine-2-spiropiperidine derivative. Patent EP1420020, Banyu Pharmaceutical Co., 2008.
162. Goehring RR, Kyle D, Lee G, Gharagozloo P, Victory S. Spiropyrazole compounds. Patent EP1385515, Euro-Celtique S.A., 2008.
163. Adam G, Cesura A, Jenck FCO, Kolczewski S, Rover S, Wichmann J. Diaza-spiro[3, 5]nonane derivatives. Patent US6113527, Hoffmann-La Roche Inc., 2000.
164. Adam G, Cesura A, Galley G, Jenck FCO, Rover S, Wichmann J. Piperidine derivatives. Patent US6166209, Hoffmann-La Roche Inc., 2000.
165. Goto Y, Arai-Otsuki S, Tachibana Y, Ichikawa D, Ozaki S, Takahashi H, Iwasawa Y, Okamoto O, Okuda S, Ohta H, Sagara T. Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. J Med Chem 2006;49:847-849.
166. Yoshizumi T, Miyazoe H, Ito H, Tsujita T, Takahashi H, Asai M, Ozaki S, Ohta H, Okamoto O. Design, synthesis, and structure-activity relationship study of a novel class of ORL1 receptor antagonists based on N-biarylmethylspiropiperidine. Bioorg Med Chem Lett 2008;18:3778-3782.
167. Goehring RR, Kyle DJ, Victory SF. Spiroindene and spiroindane compounds. EP 2033644, Euro-Celtique S.A., 2009.
168. Kolczewski S, Adam G, Cesura AM, Jenck F, Hennig M, Oberhauser T, Poli SM, Rössler F, Röver S, Wichmann J, Dautzemberg FM. Novel hexahydrospiro[piperidine-4, 1'-pyrrolo[3, 4-c]pyrroles]: Highly selective small-molecule nociceptin/orphanin FQ receptor agonists. J Med Chem 2003;46:255-264.
169. Battista KA, Bignan GC, Connolly PJ, Liu JJ, Middleton SA, Orsini MJ. Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators. Patent US 2007/0112016, Johnson & Johnson, 2007.
170. Bignan GC, Battista K, Connolly PJ, Orsini MJ, Liu J, Middleton SA, Reitz AB. Preparation of 3-spirocyclic indolin-2-ones as ligands for the ORL-1receptor. Bioorg Med Chem Lett 2005;15:5022-5026.
171. Mustazza C, Borioni A, Sestili I, Sbraccia M, Rodomonte A, Del Giudice MR. Synthesis and pharmacological evaluation of 1, 2-dihydrospiro[isoquinoline-4(3H), 4'-piperidin]-3-ones as nociceptin receptor agonists. J Med Chem 2008;51:1058-1062.
172. Mustazza C, Borioni A, Sestili I, Sbraccia M, Rodomonte A, Ferretti R, Del Giudice MR. Synthesis and evaluation as NOP ligands of some spiro[piperidine-4, 2'(1'H)-quinazolin]-4'(3'H)-ones and spiro[piperidine-4, 5'(6'H)-[1, 2, 4]triazolo[1, 5-c]quinazolines]. Chem Pharm Bull (Tokyo) 2006;54:611-622.
173. Hashizume Y, Hirota M, Mihara S, Nakamura H, Koike H, Matsumoto Y. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1 receptor antagonists. Patent US7354925, Pfizer Inc., 2008.
174. Hashizume Y, Hirota M, Mihara S, Nakamura H, Koike H, Matsumoto Y. Alpha-(aryl- or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as Orl-1 receptor antagonists. Patent US20080207665, Pfizer Inc., 2008.
175. Hashizume Y, Hirota M, Mihara S, Nakamura H, Koike H, Matsumoto Y. Alpha (aryl- or heteroaryl-methyl)-beta-piperidino propanamide compounds as Orl-1 receptor antagonists, Patent US20080200490, Pfizer Inc., 2008.
176. Shinkai H, Ito T, Iida T, Kitao Y, Yamada H, Uchida I. 4-Aminoquinolines: Novel nociceptin antagonists with analgesic activity. J Med Chem 2000;43:4667-4677.
177. 1) receptor antagonist, JTC-801. Br J Pharmacol 2002;135:323-332.
178. Sestili I, Borioni A, Mustazza C, Rodomonte A, Turchetto L, Sbraccia M, Riitano D, Del Giudice MR. A new synthetic approach of N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide (JTC-801) and its analogues and their pharmacological evaluation as nociceptin receptor (NOP) antagonists. Eur J Med Chem 2004;39:1047-1057.
179. Shinkai H, Ito T, Yamada H. Amide derivatives and nociceptin antagonists. Patent US20060030565; Japan Tobacco Inc., 2006.
180. Oyama T, Sakano K. Antipruritics. Patent US20080103163, Dreier LLP, 2008.
181. Okano M, Mori K. Quinazoline derivatives and drugs. Patent EP1340748, Nippon Shinyaku Co. Ltd., 2008.
182. Okano M, Mito J, Maruyama Y, Masuda H, Niwa T, Nakagawa S, Nakamura Y, Matsuura A. Discovery and structure-activity relationships of 4-aminoquinazoline derivatives, a novel class of opioid receptor-like 1 (ORL1) antagonists. Bioorg Med Chem 2009;17:119-132.
183. Okamoto O, Kobayashi K, Kawamoto H, Ito S, Satoh A, Kato T, Yamamoto I, Mizutani S, Hashimoto M, Shimizu A, Sakoh H, Nagatomi Y, Iwasawa Y, Takahashi H, Ishii Y, Ozaki S, Ohta H. Identification of novel benzimidazole series of potent and selective ORL1 antagonists. Bioorg Med Chem Lett 2008;18:3278-3281.
184. Okamoto O, Kobayashi K, Kawamoto H, Ito S, Yoshizumi T, Yamamoto I, Hashimoto M, Shimizu A, Takahashi H, Ishii Y, Ozaki S, Ohta H. Novel ORL-1 selective antagonists with oral bioavailability and brain penetrability. Bioorg Med Chem Lett 2008;18:3282-3285.
185. Sugimoto Y, Shimizu A, Kato T, Satoh A, Ozaki S, Ohta H, Okamoto O. Design, synthesis and biological evaluation of indole derivatives as novel nociceptin/orphanin FQ (N/OFQ) receptor antagonists. Bioorg Med Chem Lett 2006;16:3569-3573.
186. Sundermann B, Schick H, Hinze C. 4-Aminomethyl-1-aryl-cyclohexylamine compounds. Patent US7173045, Gruenenthal GmbH, 2007.
187. Sundermann B, Schick H, Hinze C. 4-Hydroxymethyl-1-aryl-cyclohexylamine compounds. Patent US7232847, Gruenenthal GmbH, 2007.
188. Hinze C, Sundermann B, Schick H, Henkel B. Cyclohexylacetic acid compounds. Patent US20070129347, Gruenenthal GmbH, 2007.
189. Hinze C, Schick H. Cyclohexylurea compounds. Patent US7348354, Gruenenthal GmbH, 2008.
190. Sundermann B, Schick H. 4-Alkyl-/4-alkenyl/4-alkynyl methyl-/1-aryl-cyclohexylamine compounds. Patent US7507758, Gruenenthal GmbH, 2009.
191. Sundermann B, Hennies HH, Englberger W, Koegel BY. Substituted 4-aminocyclohexanols. Patent US7211694, Gruenenthal GmbH, 2007.
192. Sundermann B, Maul C, Buschmann H, Heller B. Substituted 2-pyridine-cyclohexane-1, 4-diamine derivatives. Patent EP1385825, Gruenenthal GmbH, 2007.
193. Sundermann B, Hennies HH, Englberger W, Koegel BY. Substituted cyclohexane-1, 4-diamine compounds. Patent US7276518, Gruenenthal GmbH, 2007.
194. Sundermann C, Sundermann B. Cyclohexyl-1, 4-diamine compounds. Patent US7439394, Gruenenthal GmbH, 2008.
195. Hinze C, Sundermann B, Schick H, Henkel B, Englberger W, Oberbörsch S, Friderichs E, Frormann S, Kögel BY, Linz K, Merla B, Saunders D, Schröder W, Sonnenschein H. Spirocyclic cyclohexane derivatives with affinity for the ORL1 receptor. Patent WO 2005/066183, Gruenenthal GmbH, 2005.
196. Friderichs E, Kögel BY, Linz K. Spirocyclic cyclohexane compounds useful to treat substance dependency. Patent US 20080221141, Gruenenthal GmbH, 2008.
197. Linz K, Kögel BY, Schröder W, Christoph T, De Vry J, Friderichs E. Mixed ORL1/mu agonists for the treatment of pain. Patent US 2008/0125475; Gruenenthal GmbH, 2008.
198. Hinze C, Sundermann B, Oberboersch S, Englberger W, Friedrichs E, Frormann S, Koegel BY, Linz K, Merla B, Saunders D, Schroeder W, Schick H, Henkel B, Sonnenschein H. Spirocyclic cyclohexane compounds. Patent US7332519, Gruenenthal GmbH, 2008.
199. Zhou X. Phenylpropionamide compounds and the use thereof. Patent WO/2008/053352, Purdue Pharma L.P., 2008.
200. Wu WL, Caplen MA, Domalski MS, Zhang H, Fawzi A, Burnett DA. Synthesis and structure-activity relationships of aminoalkylazetidines as ORL1 receptor ligands. Bioorg Med Chem Lett 2002;12:3157-3160.
201. Merla B, Sundermann C, Jagusch UP, Englberger W, Hennies HH, Kögel BY. Substituted 5-aminomethyl-1H-pyrrole-2-carboxamides. Patent US7229991, Gruenenthal GmbH, 2007.
202. Okamoto O, Kobayashi K, Ito H, Tsujita T, Ozaki S, Ohta H. Aryl-substituted nitrogen-containing heterocyclic compound. Patent EP1935881, Banyu Pharmaceutical Co. Ltd., 2008.